12/20/2025
In the ARTESiA randomized trial subanalysis, apixaban increased the risk of major gastrointestinal bleeding compared to aspirin in patients with subclinical atrial fibrillation (SCAF), but rates of fatal and intracranial bleeding were similar between groups.
Most bleeding events were nonemergencies, driven by hemoglobin decrease, and were more likely in those using NSAIDs, with cancer, randomized to apixaban, or older age.
https://ja.ma/3L4AlXr